Perrigo Delivers FY2025 Adjusted EPS Growth and Sets Operational Cost Savings Target Up to $100 Million

Adjusted EPS Climbs 7% as Core Operating Performance Shows Resilience

Perrigo (NYSE: PRGO) reported its fourth quarter and full-year fiscal 2025 financial results, showing the company’s ability to deliver steady core performance despite challenging industry conditions. Notably, adjusted earnings per share (EPS) improved by 7% year-over-year to $2.75, reflecting fruitful cost-saving actions, disciplined execution, and persistent market share gains—even as reported results were hampered by a significant $1.3 billion goodwill impairment charge.

Cost Savings Initiatives Exceed Targets; New $80-$100M Efficiency Program Launched

Perrigo closed FY2025 with two major efficiency programs—Project Energize and the global Supply Chain Reinvention Program—each hitting the high-end of anticipated savings. Project Energize yielded $167 million in annualized gross pre-tax savings, while the supply chain effort added $157 million in annual run-rate benefits. Building on this momentum, Perrigo launched a fresh operational enhancement program targeting $80 million to $100 million in pre-tax annualized savings by the end of FY2027.

Organic Net Sales Dip Offset by Share Gains; Adjusted Margins Hold Steady

Although net sales declined 2.8% to $4.25 billion for FY2025, Perrigo’s adjusted operating performance demonstrated core strength. Excluding challenges in infant formula and divested businesses, underlying business sales were largely flat. Store brand and key branded OTC products grew share, with U.S. volume up 60 basis points and main brands capturing an additional 10 basis points in dollar share.

Despite volume pressure, gross margin on an adjusted basis held nearly steady at 38.7%, just 10 basis points lower than last year. Adjusted operating margin expanded to 14.6% (up 70 basis points) while adjusted operating income rose 2.3% to $622 million. Adjusted net income advanced to $382 million—a 7.8% improvement year-over-year.

Segment Highlights: International Division Supports Margins; Americas Navigates Infant Formula Headwinds

The Consumer Self-Care International (CSCI) segment performed strongly, with adjusted operating margins expanding 90 basis points to 21.9%, thanks to positive currency translation and new product momentum. In contrast, the Americas division (CSCA) faced a 4% sales dip, mainly from infant formula losses and subdued OTC demand, yet still delivered a stable adjusted operating margin of 15.9%.

Significant Goodwill Impairment Affects Reported Results

Perrigo’s reported net loss of $1.40 billion for FY2025 stems almost entirely from a non-cash goodwill impairment charge ($1.3 billion), triggered by lower expected cash flows in the infant formula business and adverse market conditions. While adjusted metrics filter out this effect, management warned that an additional impairment charge (up to $350 million) could follow as it transitions to new reporting units in FY2026.

2026 Outlook: CORE Business Targets Stability, Margin Expansion, and Reinvestments

Looking forward, Perrigo provided full-year guidance for both “All In” and “CORE” operations—the latter excluding the infant formula business and divested lines. CORE adjusted EPS is expected between $2.25 and $2.55 (vs. $2.52 in FY2025), with organic net sales growth ranging from -3.5% to +0.5%. Operational savings and a renewed focus on high-margin, proven brands are set to buffer ongoing volume headwinds and support the company's transition year. The company also plans to recast segment reporting beginning Q1 2026 to align with its new operating model.

Strategic Moves and Balance Sheet Readiness

Perrigo continues to optimize its portfolio, executing the planned sale of its Dermacosmetics brand business and completing its efficiency programs under budget. The company ended the year with $532 million in cash and net leverage roughly at 4x adjusted EBITDA, providing room for strategic reinvestments and shareholder returns. Capital expenditures totaled $93 million and $159 million was returned to shareholders via dividends in FY2025.

Key Takeaway for Investors

Perrigo’s FY2025 shows a company leveraging efficiency and cost discipline to offset challenging consumer and product trends. Investors looking at PRGO should keep an eye on incremental cost saves, CORE segment performance, and execution of the company’s operational enhancement as management attempts to navigate macro uncertainties and complete its stated portfolio transitions.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI